20.6 C
New York
Sunday, June 7, 2026

Tag: genetic disorders

Ractigen Therapeutics Announces ADA 2026 Late-Breaking Presentation Highlighting saRNA as a New Frontier in Obesity Control

Breakthrough preclinical data demonstrate that LiCO-saUcp1 effectively turns white fat into calorie-burning brown fat, driving massive fat loss while fully preserving lean muscle mass...

Fighting the Global Fertility Crisis! Taiwan Pioneers AI-Powered Embryo Selection Model — Improving Chromosomally Normal Embryo Identification Rate by Up to 24%

Breaking Through the "Blind Selection" Dilemma in Clinical Practice — TFC Taipei Fertility Center Introduces AI Scoring System to Help Infertile Couples End the...

IBAT Inhibitors Market Witnesses Strong Growth During the Forecast Period (2025-2034) Owing to the Rising Demand for Rare Cholestatic Liver Disease Therapies | DelveInsight

The market for IBAT inhibitors is projected to experience significant growth in the near future, fueled by the rising incidence of genetic disorders, a...

IBAT Inhibitors Market Witnesses Strong Growth During the Forecast Period (2025-2034) Owing to the Rising Demand for Rare Cholestatic Liver Disease Therapies | DelveInsight

The market for IBAT inhibitors is projected to experience significant growth in the near future, fueled by the rising incidence of genetic disorders, a...

PacBio HiFi Sequencing Powers First Arab Human Pangenome, Published in Nature Communications

Study reveals millions of previously unknown variants and genomic sequences from underrepresented populations
Study reveals millions of previously unknown variants and genomic sequences from underrepresented populations

Analysis Group Co-Authors Examine the Advancements in and Application of Health Economics and Outcomes Research to the Evaluation of Cell and Gene Therapies for...

BOSTON, July 22, 2025 /PRNewswire/ -- In a new article published in Value in Health, researchers from Analysis Group, a global leader in health economics...

Precision Era to Redefine Treatment, Drive $450B Economic Investment and Change Lives Across Asia Pacific

SINGAPORE, July 22, 2025 /PRNewswire/ -- The Precision Era of medicine is arriving in Asia Pacific, driven by the arrival of a critical mass...

Gain Therapeutics Announces Proposed Public Offering

BETHESDA, Md., July 15, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that it is proposing to offer and sell, subject to market conditions, shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase common stock in an underwritten public offering. Gain expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of common stock and/or the warrants offered in the offering. All of the securities are being offered by the Company.

Ultragenyx and Mereo BioPharma Announce UX143 Phase 3 Orbit Study for Osteogenesis Imperfecta Progressing to Final Analysis

Data from Orbit and Cosmic studies expected around the end of the year
Data from Orbit and Cosmic studies expected around the end of the year

Baylor Genetics’ Chairman and CEO Kengo Takishima Named One of Houston Business Journal’s 2025 Most Admired CEOs

Award is one of Houston’s most inspiring celebrations of leadership, where CEOs and visionaries are at the helm of the city’s most successful and impactful organizations
Award is one of Houston’s most inspiring celebrations of leadership, where CEOs and visionaries are at the helm of the city’s most successful and impactful organizations

Ascidian Therapeutics Appoints Dr. Murray A. Abramson as Chief Development Officer and Establishes Ophthalmology Clinical Advisory Board to Advance ACDN-01 for Treatment of Stargardt...

BOSTON, June 24, 2025 /PRNewswire/ -- Ascidian Therapeutics, a biotechnology company seeking to treat human diseases by rewriting RNA, today announced the appointment of Murray...

BrightSpring Health Services Announces Onco360® Selected as National Pharmacy Partner for Multiple New Cancer and Rare Disease Drugs

LOUISVILLE, Ky., June 18, 2025 (GLOBE NEWSWIRE) -- BrightSpring Health Services (“BrightSpring” or “BrightSpring Health Services”) (NASDAQ: BTSG) is proud to announce that its specialty pharmacy, Onco360®, has been selected as the national pharmacy partner for several newly approved therapies in the treatment of advanced cancers and rare genetic disorders.

Oligonucleotide Synthesis Market is expected to generate a revenue of USD 5.75 Billion by 2031, Globally, at 10.49% CAGR: Verified Market Research®

The Oligonucleotide Synthesis Market is poised for robust growth, fueled by advancements in personalized medicine, molecular diagnostics, and genomics research. However, high production costs, regulatory...

INVESTIGATION ALERT: Edelson Lechtzin LLP is investigating GeneDx Holdings Corp. (NASDAQ: WGS) and Encourages Investors with Substantial Losses to Contact the Firm

NEWTOWN, Pa., June 13, 2025 /PRNewswire/ -- Edelson Lechtzin LLP is investigating potential violations of the federal securities laws involving GeneDx Holdings Corp. ("GeneDx") (NASDAQ: WGS),...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsGenetic disorders